Adial Pharmaceuticals appoints David Rubenstein as Chief Scientist
What happened
Adial Pharmaceuticals, Inc. announced the appointment of David Rubenstein as Chief Scientist following its acquisition of Azora Therapeutics. Rubenstein will lead the company's research and scientific strategy, including the continued study of AT177, an oral aryl hydrocarbon receptor (AhR) agonist for ulcerative colitis.
From manilatimes.net
Why it matters
Rubenstein previously guided tapinarof, the first AhR agonist, through development, approval, and commercialization for plaque psoriasis and atopic dermatitis. His experience establishes AhR agonism as a clinically proven mechanism in immune-mediated inflammatory disease.
From manilatimes.net
Who's involved
- David RubensteinAppointed Chief Scientist to lead research and scientific strategy at Adial Pharmaceuticals, Inc.
- FDARegulatory body whose approval process Rubenstein previously navigated for AhR agonists
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- United States of AmericaSpeculative
The pharmaceutical industry might see increased investment in AhR agonist treatments if AT177 progresses toward regulatory approval.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- Adial's drug progress may increase value for Carlyle GroupAdial's drug development success could boost financial interests tied to Carlyle GroupPossible
- Adial's new AhR agonist may require FDA drug evaluation guidanceAdial's new drug development could engage FDA's drug evaluation centerPossible
- New AhR agonist development may increase competition for Eli LillyNew AhR agonist development may increase competition for Eli LillyPossible
Keep exploring
The entities involved
- FDA
-
David Rubenstein
American businessman (born 1949)